ABBV-075 is a novel BET inhibitor that triggers apoptosis in AML cells, non-Hodgkin lymphoma, and MM cells [102], whereas ABBV-744 selectively targets the BD2 domain, displaces BRD4 from androgen receptor (AR)-containing super-enhancers, and inhibits AR-dependent transcription. Here, BRD4 is linked to Miyoshi myopathy.